Thursday, May 4, 2017, Denver, CO, 6:00 PM – 8:00 PM (MST)

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A CNE Symposia Series Held During the 42nd Annual ONS Congress

Part 4 — Lymphomas and Chronic Lymphocytic Leukemia

Location:
Hyatt Regency Denver at the Colorado Convention Center
650 15th St
Denver, CO 80202
Hotel Phone: (303) 436-1234

Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)

Schedule (MST):
5:30 PM – 6:00 PM – Registration and Dinner Buffet
6:00 PM – 8:00 PM – Educational Program

There is no registration fee for these events. However, preregistration is required as seating is limited.

Faculty:
Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine
Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Kim Leake, MSN, FNP-C, APN-1
Division of Hematology and Oncology
University of Virginia Health System
Charlottesville, Virginia

Mollie Moran, MSN, CNP, AOCNP
The James Cancer Hospital at
The Ohio State University
Columbus, Ohio

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
University of Virginia School of Medicine
Charlottesville, Virginia

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Meeting space has been assigned to provide a satellite symposium supported by AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company and Seattle Genetics (via educational grants) during the Oncology Nursing Society’s (ONS) 42nd Annual Congress, May 3-7, 2017 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

MODULE 1: Chronic Lymphocytic Leukemia (CLL)

DISCUSSION TOPICS

  • Incidence of genetic abnormalities in CLL (eg, 13q and 17p deletions, IgVH gene mutations) and implication for long-term prognosis
  • Selection of up-front treatment for CLL in younger and older patients with normal and high-risk cytogenetics
  • Similarities and differences between obinutuzumab and rituximab; prevalence and management of infusion-related reactions associated with obinutuzumab administration
  • Integrating ibrutinib into the treatment algorithm for CLL: Activity and side-effect profile, including atrial fibrillation and risk of bleeding
  • Management of relapsed/refractory CLL: Incorporation of idelalisib and venetoclax
  • Risk of and preemptive measures to prevent tumor lysis syndrome with venetoclax
  • Mechanism of action, tolerability and ongoing investigation of the second-generation BTK inhibitor acalabrutinib

MODULE 2: Follicular Lymphoma (FL)

DISCUSSION TOPICS

  • Selection of treatment, including “watch and wait” and rituximab monotherapy, for patients with newly diagnosed FL
  • Comparative safety and efficacy of subcutaneous versus intravenous administration of rituximab in FL and other lymphomas
  • Results from the Phase III GALLIUM trial and implications for the use of obinutuzumab with chemotherapy as up-front therapy for patients with treatment-naïve FL
  • Available research data and ongoing evaluation of rituximab/lenalidomide (R2)
  • Appropriate integration of idelalisib into current treatment algorithms; recognition, prevention and management of idelalisib-related toxicities

MODULE 3: Hodgkin Lymphoma (HL)

DISCUSSION TOPICS

  • Clinical management of early-stage classical HL; long-term risks of radiation therapy
  • Relative benefits and risks of various combination chemotherapy regimens for newly diagnosed advanced-stage HL
  • Mechanism of action of brentuximab vedotin (BV) and role in the post-transplant consolidation and relapsed/refractory settings
  • Incidence and management of neuropathy and other toxicities associated with BV in HL
  • Biologic rationale for the efficacy of immune checkpoint inhibitors in HL and integration of nivolumab and pembrolizumab into the treatment algorithm for relapsed/refractory disease
  • Side effects and toxicities of anti-PD-1 antibodies; use in patients with prior autoimmune disorders

MODULE 4: Mantle Cell Lymphoma (MCL)

DISCUSSION TOPICS

  • Observation as an initial management strategy for MCL
  • Selection of front-line and maintenance therapy for younger and older patients with newly diagnosed MCL
  • Dose, schedule and duration of rituximab maintenance
  • Sequencing of available treatment options for relapsed/refractory MCL: bortezomib, lenalidomide, ibrutinib, et cetera
  • Counseling patients receiving oral therapies regarding adherence

MODULE 5: Diffuse Large B-Cell Lymphoma (DLBCL)

DISCUSSION TOPICS

  • Cell of origin as a determinant of prognosis or potential treatment course
  • Up-front treatment of newly diagnosed DLBCL
  • Management of relapsed/refractory disease, including the use of lenalidomide
  • Indications for CD30 testing and available efficacy and toxicity data with BV in relapsed/refractory disease
  • Novel agents and strategies currently under investigation in DLBCL

MODULE 6: T-Cell Lymphoma (TCL)

DISCUSSION TOPICS

  • Up-front therapy for younger and older patients with TCL; role of autologous stem cell transplant
  • Selection and sequencing of romidepsin, pralatrexate and belinostat for patients with relapsed/refractory TCL and management of side effects
  • Role of CD30 testing in TCL
  • Indications for and ongoing evaluation of BV in TCL subtypes

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Provide patient-focused education to enhance clinical decision-making regarding the available systemic agents used in the management of indolent and aggressive forms of B-cell and T-cell lymphomas and HL.
  • Appreciate the contribution of patient performance status/comorbidities, biomarker profile, prior therapeutic exposure and psychosocial status on the selection and sequence of systemic therapy for newly diagnosed and relapsed/refractory (R/R) CLL.
  • Review recent therapeutic advances in the management of newly diagnosed and R/R diffuse large B-cell, follicular and mantle cell lymphoma, and use this information to counsel patients regarding protocol and nonresearch options.
  • Consider available and emerging data informing the clinical use of brentuximab vedotin and immune checkpoint inhibitors in the therapeutic management of HL.

Accreditation Statements:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International attendees, please note: In order for a certificate of completion to be issued, you must provide a valid email address.

ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2017/ILNA

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

Research To Practice staff and external reviewers The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

Supporters:
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company and Seattle Genetics.

Hyatt Regency Denver at the Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234

Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)

The Hyatt Regency Denver at the Colorado Convention Center is the host hotel for the 2017 ONS Annual Congress.

 

Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 4 – Lymphoma and CLL session.  Onsite registration will be open starting at 5:15 PM (MST) on Thursday, May 4th.

If you are interested in standing by for seating (day of the program), please visit our registration desk located outside the Capitol Ballroom 4-7, on the fourth floor of the Hyatt Regency Denver at the Colorado Convention Center hotel (650 15th St, Denver, CO 80202).   You may arrive up to 45-minutes before the program start time and receive a stand by ticket.

If seats become available for the program, we will accept stand by registrations on a first come, first served basis. Please note onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email atMeetings@ResearchToPractice.com or call (800) 233-6153.